No attachments available.
Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers
Contact and place of performance
Nicole Belanger
Not specified
Multiple Award IDIQ to the following contractors: HHSN261201500032I, The Research Institute of Fox Chase Cancer Center HHSN261201500041I, SRI International HHSN261201500042I, IIT Research Institute HHSN261201500018I, University of Texas MD Anderson Cancer Center HHSN261201500036I, University of Alabama at Birmingham HHSN261201500037I, Medical College of Wisconsin HHSN261201500038I, University of Oklahoma Health Sciences Center HHSN261201500039I, Weill Medical College of Cornell University
The National Institutes of Health, through the Preclinical PREVENT Cancer Program, issued a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) contract focused on preclinical efficacy and intermediate endpoint biomarkers. This award notice, identified by solicitation number N01CN5500347 and published on September 25, 2015, facilitates research and development services under NAICS code 541711 and PSC code A. Nicole Belanger is the designated point of contact for this procurement.
The government selected eight contractors to support the program’s preclinical objectives: The Research Institute of Fox Chase Cancer Center (HHSN261201500032I), SRI International (HHSN261201500041I), IIT Research Institute (HHSN261201500042I), University of Texas MD Anderson Cancer Center (HHSN261201500018I), University of Alabama at Birmingham (HHSN261201500036I), Medical College of Wisconsin (HHSN261201500037I), University of Oklahoma Health Sciences Center (HHSN261201500039I), and Weill Medical College of Cornell University (HHSN261201500038I). These organizations provide specialized scientific capabilities required for the evaluation of cancer prevention strategies and biological markers.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.